SCHEMBL20544044

SCHEMBL20544044

CC=CCn1ncc(NC2CCCCN(C)C2)c(Cl)c1=O

nearest known ligand 0.76

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 20/20 0.76
▸ BPTF Q12830 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17916722 1.00 KAT2B (0.76) KAT2BBPTF
SCHEMBL17916727 0.86 KAT2B (1.00) KAT2BBPTF
SCHEMBL17916723 0.85 KAT2B (1.00) KAT2BBPTF
SCHEMBL17912347 0.81 KAT2B (1.00) KAT2BBPTF
SCHEMBL17912400 0.81 KAT2B (1.00) KAT2BBPTF
SCHEMBL17912345 0.81 KAT2B (1.00) KAT2BBPTF
SCHEMBL17912350 0.80 KAT2B (1.00) KAT2BBPTF
SCHEMBL17912366 0.79 KAT2B (1.00) KAT2BBPTF
SCHEMBL17912368 0.79 KAT2B (1.00) KAT2BBPTF
SCHEMBL17916701 0.79 KAT2B (1.00) KAT2BBPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3242874-B1 PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER GENENTECH INC (US) 2018-10-31 — — EP disclosed
Send feedback